Publication | Closed Access

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Surgical OncologyMalignant DiseaseRelapsed Malignant MesotheliomaMedicinePlacebo-controlled Phase 2BCancer TreatmentThird-line TreatmentOncologyRadiation OncologyRadiologyHealth Sciences